Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
41.87 ^USD	-1.74%		+1.58%	-12.44%

05-14	Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	MT
05-14	Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM

Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 02, 2024 at 04:00 pm

Ultragenyx Pharmaceutical Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 108.83 million compared to USD 100.5 million a year ago. Net loss was USD 170.68 million compared to USD 163.97 million a year ago.

Basic loss per share from continuing operations was USD 2.03 compared to USD 2.33 a year ago.

Latest news about Ultragenyx Pharmaceutical Inc.

Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	05-14	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM	05-14
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating	05-03	MT
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M	05-02	MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	05-02	CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta (OI)	04-30	CI
RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward	04-22	MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	04-15	DJ
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	04-15	MT
Sector Update: Health Care Stocks Advance Premarket Monday	04-15	MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	04-15
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	04-15	CI
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating	03-18	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM	03-13
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 04:20 PM	03-12
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	03-12	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM	03-04
Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating	02-21	MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday	02-16	MT
Wedbush Lifts Ultragenyx Pharmaceutical's PT to $48 From $47, Notes Fuller Catalyst Lineup for 2024; Keeps Neutral Rating	02-16	MT
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set	02-15	MT
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q4 Revenue $127.4M	02-15	MT

Chart Ultragenyx Pharmaceutical Inc.

Duration

Period

More charts

Company Profile

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Sector

Biotechnology & Medical Research

Calendar

2024-06-18 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Ultragenyx Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42.61 USD

Average target price

89 USD

Spread / Average Target

+108.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ULTRAGENYX PHARMACEUTICAL INC.	-12.44%	3.54B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs